Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine - Top-Institutions - MDSpire

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • By

  • Antonietta Liotti

  • Giorgia Teresa Maniscalco

  • Anne Lise Ferrara

  • Valeria Mazzone

  • Maedeh Dehbozorgi

  • Annamária Szabó

  • Martina Belardo

  • Daria Marcogiuseppe

  • Antonio De Martino

  • Maria Elena Di Battista

  • Giovanna Servillo

  • Ornella Moreggia

  • Daniele Di Giulio Cesare

  • Vincenzo Andreone

  • Gilda Varricchi

  • Veronica De Rosa

  • June 16, 2026

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Neuroimmunology and Multiple Sclerosis Center of the Cardarelli Hospital
    Neuroimmunology and Multiple Sclerosis Center of the Cardarelli Hospital

    Naples, Italy

    Key Differentiators

    • Neurology

Original Source(s)

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • by Antonietta Liotti, Giorgia Teresa Maniscalco, Anne Lise Ferrara, Valeria Mazzone, Maedeh Dehbozorgi, Annamária Szabó, Martina Belardo, Daria Marcogiuseppe, Antonio De Martino, Maria Elena Di Battista, Giovanna Servillo, Ornella Moreggia, Daniele Di Giulio Cesare, Vincenzo Andreone, Gilda Varricchi, Veronica De Rosa

  • June 16, 2026

Related Content

A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity

Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis